Strategic and Technology-Driven M&A Surge in Pharma Sector in Early June 2026

　　【Pharmaceutical Network | Industry Trends] In early June 2026, the pharmaceutical industry witnessed several significant mergers and acquisitions, ranging from strategic moves by leading enterprises in the diagnostics sector to traditional pharmaceutical companies supplementing their industrial chains.
 

　　Dikang Pharmaceutical Acquires 75% Equity Stake in Bairui ShengwuKeji
 

On June 5, Dikang Pharmaceutical, a subsidiary of Hanshang Group, acquired a 75% equity stake in Ningbo Bairui ShengwuKeji Co., Ltd. It is understood that Bairui ShengwuKeji has deeply cultivated the fields of sports medicine and orthopedics, focusing on the research and development, production, and market promotion of absorbable high-value consumables. The company boasts a comprehensive product portfolio and has currently obtained four Class III medical device registration certificates. Its four core products—absorbable suture anchors, looped titanium plates, all-suture anchors, and absorbable sheathed interference screws—have been successfully approved for market launch.
 

Chengdu Dikang Technology Pharmaceutical Stock Co., Ltd. stated that, through this acquisition, the successful experience of Bairui ShengwuKeji would help Dikang Pharmaceutical grasp the key points of intrinsic quality control for absorbable materials (including composite materials), identify the correct direction for material research and development, and further enhance its materials platform. Meanwhile, the acquisition will strengthen its technological accumulation and market layout in high-end medical device sectors such as sports medicine, thereby potentially improving the listed company’s performance and effectively accelerating the process of domestic substitution for sports medicine consumables in China.
 

　　China National Pharmaceutical Group Corporation Takes Control of Amoy Diagnostics with RMB 1.654 Billion Investment
 

On June 5, Amoy Diagnostics disclosed an announcement regarding a change in control. China National Pharmaceutical Group Corporation (Sinopharm) plans to invest RMB 1.654 billion to acquire a 20% equity stake in the company, thereby becoming its actual controlling shareholder. As one of the few domestic IVD enterprises qualified for companion diagnostic collaborations with multinational corporations (MNCs), Amoy Diagnostics’ core product portfolio covers gene mutation detection kits for solid tumors, including lung cancer, colorectal cancer, breast cancer, and thyroid cancer. Through this acquisition, Sinopharm will complete its full “diagnosis–treatment” business chain and enhance its competitiveness in drug research, development, and commercialization via “pharma + diagnostics” synergy.
 

It is reported that in recent years, China National Pharmaceutical Group Corporation has accelerated its layout of A-share listed companies through intensive capital operations. In addition to the proposed takeover of Amoy Diagnostics Co., LTD, the company is also advancing the takeovers of Pacific Shuanglin Bio-pharmacy Co., Ltd. and Shenzhen Weiguang Biological Products Co., Ltd. In the future, the number of A-share listed companies controlled by China National Pharmaceutical Group Corporation is expected to exceed 10.
 

Jinyao Pharmaceutical Acquires 100% Equity Interest in Jinyao Logistics for RMB 130 Million
 

Jinyao Pharmaceutical announced on June 5 that the company plans to acquire 100% equity of Jinyao Logistics through cash payment, with a transaction consideration of RMB 130 million. Jinyao Pharmaceutical stated that this acquisition of equity assets will effectively integrate the logistics system, complete the company's full industrial chain layout, further improve warehousing and distribution management efficiency, and effectively reduce the company's comprehensive logistics costs.
 

Data shows that Tianjin Pharmaceutical Co., Ltd. is mainly engaged in steroid hormones, amino acidsActive Pharmaceutical Ingredientas well as the research and development, production, and sales of pharmaceutical preparations. It is reported that Jinpharm Logistics generated revenues of RMB 22.9218 million and RMB 9.0218 million in 2025 and the first five months of 2026, respectively, with net profits of RMB 6,200 and RMB 468,500, respectively.
 

Overall, the recent wave of mergers and acquisitions indicates that as the industry shifts from “growth-driven dividends” to “zero-sum competition in a saturated market,” consolidation has become a major trend. In the future, industry concentration will accelerate, with leading companies expanding against the tide while smaller players may face accelerated exit from the market.
 

　　Disclaimer: Under no circumstances shall the information contained herein or the opinions expressed constitute investment advice to any person.